Clinical Trial Update: Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating zoledronic acid for primary breast cancer with minimal residual disease in the bone marrow was terminated. The document notes the TER…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Zometa (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Breast Cancer | Phase 2 | Status: TERMINATED